How to appeal an Elevance Health chronic wound care denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Elevance Health-specific note: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.

What Elevance Health's policy requires for chronic wound care

Cited policy: BCBS Medical Policy: Bioengineered Skin and Soft Tissue Substitutes (BCBSA Ref. )

Patterned on CMS LCD L35041: dehydrated human amnion-chorion membrane (dHACM, EpiFix Q4186) for DFU or VLU >=4 weeks failed standard care, ABI >=0.65, no untreated osteomyelitis or active deep infection, <50% area reduction with conventional therapy. Up to 8-10 applications per episode with documented progress. Vascular workup required before initiation.

How Elevance Health denies chronic wound care — and how to counter it

Where Elevance Health pushes back: 1) Use cheaper CTP first (Apligraf / Dermagraft); 2) Insufficient evidence vs SOC; 3) >5 applications excessive; 4) Provider not specialty-credentialed.

Counter-arguments that hold up: Cite Zelen Int Wound J 2013;10(5):502-507 (DFU N=25 healing 92% dHACM vs 8% standard care, p<0.001 — fastest published DFU healing rate) + Zelen Int Wound J 2015;12(6):724-732 (head-to-head dHACM vs Apligraf vs SOC; dHACM superior at 4 + 6 wk closure) + Serena Vasc Endovasc Surg 2014 (VLU). HCPCS Q4186 reimbursed under standard ASP+6% — formulary tier preference cannot override medical necessity. CMS LCD L35041 does not mandate failure of one CTP before another; physician selects based on wound characteristics, depth, exudate, and prior history.

What Elevance Health typically denies for chronic wound care

Across Elevance Health's commercial and Medicare books, denials cluster around a small number of patterns. For chronic wound care, expect:

• Step therapy
• Medical necessity for biologics
• Out-of-network for behavioral health
• Bariatric surgery prior auth

Treatments most often denied in this category

These are the chronic wound care treatments most often flagged for prior auth, step therapy, or medical necessity review:

• HBOT
• NPWT (wound vac)
• Apligraf
• Dermagraft
• EpiFix (dHACM)
• Grafix

How to submit the appeal to Elevance Health

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Elevance Health cited in the denial.
3. File the appeal through Elevance Health's portal (members: https://www.anthem.com ; providers: https://providers.anthem.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In IN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Elevance Health's prior-authorization criteria by drug: Elevance Health PA criteria on ApprovalHelp.